Skip to Content

M161 M161 (Didanosine delayed release 250 mg)

Pill imprint M161 M161 has been identified as Didanosine delayed release 250 mg.

Didanosine is used in the treatment of nonoccupational exposure; hiv infection and belongs to the drug class nucleoside reverse transcriptase inhibitors (NRTIs). There is no proven risk in humans during pregnancy. Didanosine 250 mg is not a controlled substance under the Controlled Substance Act (CSA).

Didanosine delayed release 250 mg M161 M161
Discount Card Promo
Didanosine delayed release
Imprint:
M161 M161
Strength:
250 mg
Color:
Yellow
Shape:
Capsule-shape
Availability:
Prescription only
Drug Class:
Nucleoside reverse transcriptase inhibitors (NRTIs)
Pregnancy Category:
B - No proven risk in humans
CSA Schedule:
Not a controlled drug
Manufacturer:
Mylan Pharmaceuticals Inc.
National Drug Code (NDC):
00378-8888
Inactive Ingredients:
ferrosoferric oxide
carboxymethylcellulose sodium
silicon dioxide
diethyl phthalate
gelatin
hypromelloses
methacrylic acid - methyl methacrylate copolymer (1:1)
propylene glycol
ferric oxide red
shellac
trisodium citrate dihydrate
sodium lauryl sulfate
sodium starch glycolate type A potato
magnesium silicate
titanium dioxide
ferric oxide yellow
potassium hydroxide

More info Print Imprint Search

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.

Hide